Developer docs
API playgroundTry for free, no card

Search company profiles

StemCells

Full company profile

uuid00373dn

Namestring
StemCells
Company typeenum
Private
Founded yearint
1992
Descriptiontext

StemCells, Inc. was a development-stage biotechnology company founded in 1992 by Irving Weissman and Fred Gage and headquartered in Newark, California. The company focused on the research, development, and commercialization of cell-based therapeutics and supporting tools for stem cell and regenerative medicine applications, with a flagship program built around proprietary HuCNS-SC human central nervous system stem cell technology targeting disorders of the central nervous system. Operationally it operated as a clinical-stage biotech with 51-100 employees during its active period, funded historically through equity financing including a $20 million round in July 2014.

The company was publicly listed on NASDAQ under the ticker STEM prior to its delisting, and its leadership roster during the operating period included Martin McGlynn as President & CEO and Graham Macdonald and Richard Barker as successive Chairmen of the Board. In August 2016 StemCells announced an acquisition of Microbot Medical for an undisclosed amount. Subsequently the company ceased operating as a going concern; the stemcellsinc.com domain that previously hosted corporate content now displays unrelated Greek philosophical prose, and no current operating disclosures, product portfolio, headcount, customer base, or revenue figures are present in the available evidence. As a result, no live commercial operations, products, or revenue can be verified.

Given the absence of product approvals, no disclosed pricing, no customer relationships, and no active revenue stream, the business model that historically applied was a development-stage biotech construct: capital raised from public-equity and private-placement investors funded preclinical and clinical research, with revenue contingent on future therapeutic commercialization or partnership/out-licensing economics rather than near-term product sales. Today StemCells has no verifiable active operations.

Short descriptiontext

StemCells, Inc. was a development-stage biotechnology company that researched and developed cell-based therapeutics, notably HuCNS-SC neural stem cell technology, targeting central nervous system disorders. Founded in 1992 by Weissman and Gage, it was later delisted from NASDAQ and is no longer operating.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
stem cell therapeutics, cell-based therapies, regenerative medicine, neural stem cells, biopharmaceutical research
Industry1 code
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cell-Based Therapeutics
Social media profiles2 records
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

StemCells, Inc. was engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell applications. The company's work focused on regenerative medicine, including the development of human neural stem cell-based products designed to treat disorders of the central nervous system and other conditions addressable through cell-based approaches.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Cell-based therapeutics
CategoryCell-Based Therapeutics
Description

Cell-based therapeutic candidates developed for use in regenerative medicine applications, including neural and other tissue indications, intended for pharmaceutical and clinical research customers.

2Stem cell research tools
CategoryResearch Tools
Description

Stem cell research tools and related offerings intended for academic and commercial research institutions conducting stem cell biology and translational research.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1Athersys
TypeDirect peer
Description

Clinical-stage regenerative medicine company developing MultiStem cell therapy for stroke and trauma; overlapped with StemCells in CNS/cell therapy indications.

TypeDirect peer
Description

Pre-revenue stem cell therapy developer focused on neural and hepatic applications, with similar clinical stage and capital-constrained profile as the original StemCells, Inc.

TypeEmerging player
Description

Bayer-owned iPSC-derived cell therapy developer with active CNS and cardiac programs; represents the modern direction of neural cell therapy that a reactivated StemCells entity would compete against.

TypeDirect peer
Description

Cell therapy company that acquired the Spinal Cord Injury program assets from StemCells, Inc., making it a direct corporate successor and most precise peer for residual CNS programs.

TypeDirect peer
Description

Historic stem cell therapy peer that also delisted its human embryonic stem cell program and pivoted to oncology; directly comparable in lifecycle, capital constraints, and clinical attrition experienced by StemCells, Inc.

6ViaCyte
TypeDirect peer
Description

Pioneer in stem cell-derived pancreatic islet cell therapies; comparable in being a long-duration clinical cell therapy developer with similar capital intensity profile.

TypeBroad incumbent
Description

Commercial-stage cell therapy company (remestemcel-L, Ryoncil) and a broad incumbent in regenerative medicine; comparable regulator pathway and production challenges around cell-based therapeutics.

TypeDirect peer
Description

Developed neural stem cell therapies for CNS indications (ALS, spinal cord injury) using a cell transplant approach directly analogous to StemCells' HuCNS-SC platform.

TypeBroad incumbent
Description

Clinical-stage cell and gene therapy developer with CNS-focused programs; comparable delivery modality (cell-based) and indication mix.

TypeDirect peer
Description

Develops autologous stem cell therapies (NurOwn) for neurodegenerative diseases (ALS, MS); directly comparable therapeutic area and cell-based modality to StemCells' CNS focus.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StemCells

Cell-Based Therapeuticsstemcellsinc.com

StemCells, Inc. was a development-stage biotechnology company that researched and developed cell-based therapeutics, notably HuCNS-SC neural stem cell technology, targeting central nervous system disorders. Founded in 1992 by Weissman and Gage, it was later delisted from NASDAQ and is no longer operating.

What StemCells does

StemCells, Inc. was a development-stage biotechnology company founded in 1992 by Irving Weissman and Fred Gage and headquartered in Newark, California. The company focused on the research, development, and commercialization of cell-based therapeutics and supporting tools for stem cell and regenerative medicine applications, with a flagship program built around proprietary HuCNS-SC human central nervous system stem cell technology targeting disorders of the central nervous system. Operationally it operated as a clinical-stage biotech with 51-100 employees during its active period, funded historically through equity financing including a $20 million round in July 2014.

The company was publicly listed on NASDAQ under the ticker STEM prior to its delisting, and its leadership roster during the operating period included Martin McGlynn as President & CEO and Graham Macdonald and Richard Barker as successive Chairmen of the Board. In August 2016 StemCells announced an acquisition of Microbot Medical for an undisclosed amount. Subsequently the company ceased operating as a going concern; the stemcellsinc.com domain that previously hosted corporate content now displays unrelated Greek philosophical prose, and no current operating disclosures, product portfolio, headcount, customer base, or revenue figures are present in the available evidence. As a result, no live commercial operations, products, or revenue can be verified.

Given the absence of product approvals, no disclosed pricing, no customer relationships, and no active revenue stream, the business model that historically applied was a development-stage biotech construct: capital raised from public-equity and private-placement investors funded preclinical and clinical research, with revenue contingent on future therapeutic commercialization or partnership/out-licensing economics rather than near-term product sales. Today StemCells has no verifiable active operations.

StemCells firmographics

Firmographics
Name
StemCells
Website
https://stemcellsinc.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
51–100 employees
Short description
StemCells, Inc. was a development-stage biotechnology company that researched and developed cell-based therapeutics, notably HuCNS-SC neural stem cell technology, targeting central nervous system disorders. Founded in 1992 by Weissman and Gage, it was later delisted from NASDAQ and is no longer operating.
Ownership category
akta.pro rank

StemCells industry classification

Industry
Product category
Cell-Based Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Stem cell therapeutics
  • Cell-based therapies
  • Regenerative medicine
  • Neural stem cells
  • Biopharmaceutical research

Where StemCells is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Markets served

StemCells business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

StemCells product offering

Product offering

Core offering

StemCells, Inc. was engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell applications. The company's work focused on regenerative medicine, including the development of human neural stem cell-based products designed to treat disorders of the central nervous system and other conditions addressable through cell-based approaches.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell-based therapeutics Cell-based therapeutic candidates developed for use in regenerative medicine applications, including neural and other tissue indications, intended for pharmaceutical and clinical research customers.
  • Stem cell research tools Stem cell research tools and related offerings intended for academic and commercial research institutions conducting stem cell biology and translational research.

Companies that use StemCells

Customer profile

Ideal customer profiles2 records

StemCells technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

StemCells partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

StemCells competitors and assessment

Company assessment

Direct peers

  • Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for stroke and trauma; overlapped with StemCells in CNS/cell therapy indications.
  • International Stem Cell Corporation: Pre-revenue stem cell therapy developer focused on neural and hepatic applications, with similar clinical stage and capital-constrained profile as the original StemCells, Inc.
  • Lineage Cell Therapeutics: Cell therapy company that acquired the Spinal Cord Injury program assets from StemCells, Inc., making it a direct corporate successor and most precise peer for residual CNS programs.
  • Geron Corporation: Historic stem cell therapy peer that also delisted its human embryonic stem cell program and pivoted to oncology; directly comparable in lifecycle, capital constraints, and clinical attrition experienced by StemCells, Inc.
  • ViaCyte: Pioneer in stem cell-derived pancreatic islet cell therapies; comparable in being a long-duration clinical cell therapy developer with similar capital intensity profile.
  • Neuralstem: Developed neural stem cell therapies for CNS indications (ALS, spinal cord injury) using a cell transplant approach directly analogous to StemCells' HuCNS-SC platform.
  • BrainStorm Cell Therapeutics: Develops autologous stem cell therapies (NurOwn) for neurodegenerative diseases (ALS, MS); directly comparable therapeutic area and cell-based modality to StemCells' CNS focus.

Emerging players

  • BlueRock Therapeutics: Bayer-owned iPSC-derived cell therapy developer with active CNS and cardiac programs; represents the modern direction of neural cell therapy that a reactivated StemCells entity would compete against.

Broad incumbents

  • Mesoblast: Commercial-stage cell therapy company (remestemcel-L, Ryoncil) and a broad incumbent in regenerative medicine; comparable regulator pathway and production challenges around cell-based therapeutics.
  • Sangamo Therapeutics: Clinical-stage cell and gene therapy developer with CNS-focused programs; comparable delivery modality (cell-based) and indication mix.

Market position

Strengths2 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

StemCells social profiles

Digital presence

StemCells financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StemCells leadership team

Management profile

Number of profiles

Profiles5 records

StemCells funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StemCells M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemCells

What does StemCells do?

StemCells, Inc. was engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell applications. The company's work focused on regenerative medicine, including the development of human neural stem cell-based products designed to treat disorders of the central nervous system and other conditions addressable through cell-based approaches.

Is StemCells a public or private company?

StemCells is a private company. It is classified as unknown and is currently operating.

When was StemCells founded?

StemCells was founded in 1992. It employs 51 to 100 people.

Where is StemCells based?

StemCells is headquartered in Newark, United States, in the North America region.

Who are StemCells's main competitors?

Direct peers on record are Athersys, International Stem Cell Corporation, Lineage Cell Therapeutics, Geron Corporation, ViaCyte, Neuralstem and BrainStorm Cell Therapeutics. BlueRock Therapeutics is listed as an emerging player. Broad incumbents are Mesoblast and Sangamo Therapeutics.

Does StemCells have an API?

No public API is recorded for StemCells.

What industry is StemCells in?

StemCells's product category is Cell-Based Therapeutics. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalRepairing Teeth using Stem CellsDental stem cells from pulp, periodontal ligament, and root apical papilla can differentiate into odontoblasts and regenerate dental tissue. Studies show they can fill root canals with dentin and support periodontal regeneration, offering a promising alternative to implants.News-MedicalStem cells used to combat COVID-19 pneumoniaA team from the University of North Texas Health Science Center reported that intravenous infusion of clinical-grade human mesenchymal stem cells safely and effectively treated seven critically ill COVID-19 patients in Beijing, all recovering within 14 days. Of the three placebo recipients, one died and two became critically ill. The study will be published in the April 2020 issue of Aging and Disease.News-MedicalMayo Clinic study uncovers stem cell-activated mechanisms of healing after heart attackMayo Clinic researchers found that human cardiopoietic stem cells reverse heart attack damage in mice, restoring cardiac muscle to pre-disease state. The therapy reversed two-thirds of disease-induced changes, with 85% of cellular functional categories responding favorably. The findings may guide future stem cell therapies for heart disease.PrwebNew study identifies trigger that turns dormant cancer stem cells into active onesA study in STEM CELLS identified two distinct cervical cancer stem cell phenotypes, with cPLA2α overexpression triggering dormant cells to become active and metastatic. The enzyme regulates reversible transitions between epithelial and mesenchymal states via PKCζ, suggesting cPLA2α as a therapeutic target to halt recurrence and metastasis.GlobeNewswireStemCells, Inc. Encourages Stockholders to Return Proxies Approving the Microbot Merger by November 14, 2016StemCells, Inc. reported that four of five merger proposals with Microbot were approved at its special stockholder meeting, with Proposal 1 still pending. Approximately 3.8 million shares voted on Proposal 1, with 95.97% in favor, and the meeting will resume on November 14, 2016, to collect additional votes.GlobeNewswireStemCells, Inc. and Microbot Medical Ltd. Announce Strategic MergerStemCells, Inc. and Microbot Medical Ltd. announced a definitive merger agreement to develop robotics-based medical devices for cerebrospinal fluid and gastrointestinal disorders. The deal is subject to shareholder and regulatory approvals, and StemCells will negotiate creditor reductions to satisfy closing conditions.PR NewswireGlobal Strategic Development of Neural Stem & Progenitor Cell Products Market 2016-2020 - Patent Analysis for the NSC Sector - Research and MarketsResearch and Markets released a report on the strategic development of neural stem and progenitor cell products, covering terminology, market size projections for 2016-2020, and patent analysis. The report includes findings on recent advances, clinical trial activity, and company profiles for industry leaders.GlobeNewswireStemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of DataStemCells, Inc. terminated its Phase II Pathway Study in spinal cord injury after an interim analysis showed the treatment effect was unlikely to meet the primary endpoint. The company will wind down operations, evaluate IP monetization, and may distribute cash to stockholders. It plans to present Cohort I data at the ISSCR meeting.GlobeNewswireStemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway StudyStemCells, Inc. will present top-line 12-month data from Cohort I of its Pathway Study in the first quarter 2016 analyst call. The study uses HuCNS-SC neural stem cells for chronic spinal cord injury, with six-month results showing improved muscle strength and fine motor skills. Final data will be released at a scientific venue in June.GlobeNewswireStemCells, Inc. Announces 1-for-12 Reverse Stock SplitStemCells, Inc. approved a 1-for-12 reverse stock split at its May 5, 2016 annual meeting, effective May 9, 2016. The split reduces outstanding shares from about 140 million to 11.6 million, aiming to meet Nasdaq listing requirements and raise capital for clinical efforts.